
Research published by the British Medical Journal has suggested that paracetamol provides “minimal short-term benefit” in osteoarthritis, and is “ineffective” in treating low back pain.
Study authors analyzed data from 13 randomized studies, and concluded that the data suggested recommendations to use paracetamol in these patients should be re-evaluated. The results showed that paracetamol is inefficient in reducing pain intensity and disability or improving short-term quality of life in patients with low back pain. In hip or knee osteoarthritis, there was evidence that the drug provides a significant but not clinically important effect on short-term pain and disability.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze